August 01, 2025 - The increasing prevalence of chronic and genetic diseases is a major factor driving revenue growth in the gene expression analysis ...

The outcome of this study could significantly impact Sanofi’s stock performance and investor sentiment, as successful results may position Teplizumab as a leading treatment for Type 1 Diabetes. This ...